GSK’s RSV Vaccine Arexvy: FDA Expands Age Approval

The U.S. Food and Drug Administration has broadened the approval of GSK’s Arexvy, a vaccine designed to protect against respiratory syncytial virus (RSV), to include a wider age range. This expansion, announced Friday, now encompasses adults aged 18 to 49 who are at increased risk of severe lower respiratory tract disease (LRTD) caused by RSV. Reuters Health Information reports this decision could significantly impact a larger segment of the U.S. Population vulnerable to the virus.

Understanding RSV and the Expanded Vaccine Eligibility

RSV is a common respiratory virus that typically causes mild, cold-like symptoms. However, it can be serious, even life-threatening, for certain populations, including older adults and young children. The initial approval of Arexvy in the U.S. Covered adults 60 years and older, and those aged 50-59 at increased risk. This latest move addresses a substantial medical need for younger adults with underlying health conditions that make them more susceptible to severe RSV illness. According to GSK, approximately 21 million adults under 50 in the U.S. Have at least one risk factor for severe RSV infection. GSK’s press release details that these risk factors include chronic cardiopulmonary, kidney, or renal disease, obesity, and diabetes.

Lower respiratory tract disease (LRTD) encompasses conditions like bronchiolitis and pneumonia. RSV is a leading cause of these illnesses, particularly during the fall and winter months. The virus spreads through close contact with infected individuals, often via respiratory droplets produced when coughing or sneezing.

Evidence Supporting the Age Expansion

The FDA’s decision to expand Arexvy’s approval was based on data from a Phase IIIb clinical trial (NCT06389487) which demonstrated a comparable immune response in adults aged 18-49 compared to those 60 years and older. GSK highlights that earlier Phase III trial data (NCT04886596) also demonstrated vaccine efficacy. It’s important to note that these trials assess the vaccine’s ability to stimulate an immune response; real-world effectiveness in preventing LRTD will require ongoing surveillance.

The trials’ methodologies involved measuring antibody levels in participants after vaccination. While a strong antibody response is generally associated with protection against infection, it doesn’t guarantee it. Further research is needed to determine the duration of protection offered by Arexvy and how well it performs against different RSV strains.

Burden of RSV in Younger Adults

The annual impact of RSV among U.S. Adults aged 18-49 is substantial. GSK estimates approximately 17,000 hospitalizations, 277,000 emergency department visits, and 1.97 million outpatient visits are attributable to RSV each year. These figures underscore the potential public health benefit of expanding vaccination efforts to include this age group, particularly those with pre-existing conditions.

Arexvy: What You Need to Recognize

Arexvy is an adjuvanted vaccine, meaning it contains an ingredient designed to enhance the immune response. It is not intended for use in pregnant individuals. The vaccine is administered as a single dose, typically during the fall or winter months to provide protection during the RSV season.

The FDA’s approval letter, dated March 12, 2026, also includes a requirement for a warning regarding the potential risk of Guillain-Barré Syndrome (GBS) in the prescribing information for both Arexvy and another RSV vaccine, Abrysvo. The FDA website provides detailed information about this safety consideration. GBS is a rare neurological disorder in which the body’s immune system attacks the nerves.

Public Health Implications and Next Steps

This expanded approval represents a significant step forward in RSV prevention. The Centers for Disease Control and Prevention (CDC) will now review the FDA’s decision and provide recommendations regarding the use of Arexvy in adults aged 18-49. These recommendations will likely address specific populations who should prioritize vaccination, as well as optimal timing for administration.

Ongoing surveillance will be crucial to monitor the vaccine’s effectiveness in real-world settings and to identify any potential safety concerns. The CDC’s existing RSV surveillance systems, which track hospitalizations and mortality rates, will play a key role in this process. Healthcare providers are encouraged to report any adverse events following vaccination to the Vaccine Adverse Event Reporting System (VAERS).

Further research is also planned to evaluate the long-term impact of Arexvy on RSV-related healthcare utilization and to assess its effectiveness against emerging RSV variants. The goal is to refine vaccination strategies and ensure that the benefits of the vaccine continue to outweigh any potential risks.

What to expect moving forward: The CDC’s Advisory Committee on Immunization Practices (ACIP) will meet to discuss the new FDA approval and formulate official recommendations for Arexvy use in the expanded age group. These recommendations will guide clinical practice and inform public health messaging.